← Back to Treatments
🏅 FDA Orphan Designation

Tafinlar Capsules and Mekinist Tablets

dabrafenib and trametinib

Manufacturer: Novartis Pharmaceuticals Corporation

Indicated for:
Anaplastic thyroid carcinoma

FDA-Approved Indications (1)

indicated, in combination with dabrafenib and trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfa…

Population: patients with locally advanced or metastatic disease

Indications & Usage

MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options ||| TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.